| Company Name: |
Manhag Testing Technology Co., Ltd
|
| Tel: |
400-818 0104 18918165978 |
| Email: |
zilin.ren@bestown.net.cn |
| Products Intro: |
Product Name:Raltegravir-[d6]
CAS:1100750-98-8
Purity:1mg Package:1mg
|
| Company Name: |
Shanghai Beiwanta Biotechnology Co., Ltd.
|
| Tel: |
021-67187366 19901745723 |
| Email: |
info@bwtlab.com |
| Products Intro: |
Product Name:2H6]-Raltegravir
CAS:1100750-98-8
Purity:95+ Package:1mg;5mg;10mg;20mg
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
| Products Intro: |
Product Name:Raltegravir-[D6] (Standard)
CAS:1100750-98-8
Package:1mg/RMB 5110
|
|
| | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- Basic information |
| Product Name: | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- | | Synonyms: | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-;Raltegravir-[D6] (Standard) | | CAS: | 1100750-98-8 | | MF: | C20H15D6FN6O5 | | MW: | 450.453313868 | | EINECS: | | | Product Categories: | | | Mol File: | 1100750-98-8.mol | ![4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- Structure](CAS/20200401/GIF/1100750-98-8.gif) |
| | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- Chemical Properties |
| | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- Usage And Synthesis |
| Uses | Raltegravir-d6 is a deuterated labeled Raltegravir[1]. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection. | | in vivo | Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy[6]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. DOI:10.1124/mol.111.073189
[3] Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62. DOI:10.1073/pnas.1010246107
[4] Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. DOI:10.1007/s11481-017-9755-4
[5] Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9 DOI:10.1086/597290
[6] Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21. DOI:10.1186/1742-4690-7-21
[7] Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6 DOI:10.1128/AAC.06407-11 |
| | 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl-2,3,5,6-d4)methyl-d2]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo- Preparation Products And Raw materials |
|